<DOC>
	<DOCNO>NCT02093871</DOCNO>
	<brief_summary>To confirm safety 6 cycle Perfusion Induced Systemic Hyperthermia ( PISH ) provide every 28 day 3rd line ovarian cancer patient .</brief_summary>
	<brief_title>A Phase 1 Trial Perfusion Induced Systemic Hyperthermia ( PISH ) Over Multiple Cycles Terminal Ovarian Cancer</brief_title>
	<detailed_description>This study prospective , single-arm phase I trial 20 ovarian cancer patient treat PISH 6 cycle , deliver every 28 day . This mimic chemotherapy treatment , concordance fractional cell kill hypothesis cytotoxic agent . As study safety , , metastatic peritoneal ovarian cancer , histology ( epithelial , sex-cord stromal , germ cell , sarcoma ) progress 2 cycle chemotherapy , consider incurable , include . All patient must meet performance status organ function entry criterion . Patients must first undergo standard first line primary surgery chemotherapy , go fail second line chemotherapy treatment , ( without secondary cytoreductive surgery ) . Patients must candidate , expect treatment , usual third line chemotherapy agent palliation traditionally offer medical oncology . Patients may receive treatment beyond third-line therapy , long meet entry requirement study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<criteria>Age &gt; 18 year Patients ovarian cancer/primary peritoneal cancer histologic subtype , include epithelial , germ cell , sexcord stromal , sarcoma . Failure first line surgery chemotherapy , AND least second line chemotherapy , without secondary cytoreductive surgery Patients must eligible , expect treatment , FDA approve chemotherapy regimen commonly use disease per community standard . Female patient , age 1869 year old , must aware investigational nature treatment , indicate inform consent IRBapproved write process . All patient must performance status ( Karnofsky score ) great 80 Patients may treat radiotherapy , nonchemotherapy antineoplastic ( e.g . antiangiogenic agent like bevicizumab ) Hematologic Parameters : WBC &gt; 4,000/μl ANC &gt; 1500/μl , Platelet count &gt; 100,000/μl Renal Filtration : pretreatment measure calculated creatinine clearance &gt; 50 ml/minute CockroftGault equation MDRD Electrolytes parameter : Patients pretreatment serum calcium normal ( 8.510.5 mg/dL ) range . Liver function parameter : Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; AST ALT ≤ 2.5 time ULN ; Alkaline phosphatase ≤ 2.5 time ULN ; PT/INR ≤ 1.5 time ULN ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin ) Patients would expect receive benefit , third recurrence , platinumbased regimen chemotherapy Uncontrolled hypertension , define systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mm Hg Myocardial infarction unstable angina within past 6 month NYHA class IIIV congestive heart failure Atrial fibrillation ( AF ) Supra Ventricular Tachycardia ( SVT ) whether control drug ; Any serious arrhythmia , require medication control Currently anticoagulation DVT PE . Peripheral vascular disease ≥ CTCAE grade 2 ( least brief [ &lt; 24 hr ] episodes ischemia manage nonsurgically without permanent deficit ) CNS metastases Lung disease , pulmonary function test ( PFT ) FEV1 &lt; 50 % expect . Patients treat chemotherapy biologic therapy within previous 21 day . Subjects unable unwilling comply followup schedule requirement sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Therapeutic hyperthermia</keyword>
	<keyword>HEATT</keyword>
	<keyword>whole body hyperthermia</keyword>
	<keyword>hyperthermia</keyword>
	<keyword>PISH</keyword>
	<keyword>Verthermia</keyword>
	<keyword>Phase 1 clinical trial</keyword>
	<keyword>stage 3 ovarian cancer</keyword>
	<keyword>stage 4 ovarian cancer</keyword>
	<keyword>stage III ovarian cancer</keyword>
	<keyword>stage IV ovarian cancer</keyword>
	<keyword>late stage ovarian cancer</keyword>
	<keyword>Core HFC</keyword>
	<keyword>Lilja</keyword>
	<keyword>Vertrees</keyword>
	<keyword>Bastidas</keyword>
	<keyword>total body hyperthermia</keyword>
</DOC>